Immuno-Oncology | Specialty

NSCLC Findings Support Upfront Immunotherapy

September 2nd 2018

In the setting of advanced non–small cell lung cancer, the choice of up-front immunotherapy or chemotherapy, or combinations of both, is aided by findings from several trials.

Dr. Reardon on Efficacy/Safety of Immunotherapy Combination in Glioblastoma

August 31st 2018

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the safety and efficacy data of an immunotherapy combination in glioblastoma.

Dr. Naidoo on Treating Immune-Related Adverse Events in NSCLC

August 31st 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses the treatment of patients with non–small cell lung cancer who develop immune-related adverse events (irAEs).

Optimizing Checkpoint Inhibitors Requires Careful AE Management

August 31st 2018

Jarushka Naidoo, MBBCh, discusses the toxicities associated with the use of immunotherapy in oncology, optimal methods of managing them, and the growing body of knowledge on why they occur.

Bunn Discusses Future of Immunotherapy in SCLC

August 30th 2018

Paul A. Bunn Jr, MD, discusses the potential for new agents to treat small cell lung cancer, the challenges involved in treating this population, and the ongoing search for biomarkers to guide treatment decisions.

Brahmer Highlights Immunotherapy Breakthroughs in Metastatic NSCLC

August 30th 2018

Julie R. Brahmer, MD, provides an overview of the landscape of metastatic non–small cell lung cancer, specifically addressing the combination immunotherapy studies with the greatest impact.

Dr. Munshi on the Role of Checkpoint Inhibitors in Myeloma

August 29th 2018

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the role of checkpoint inhibitors in myeloma.

Camidge Captures Complexities of Immunotherapy in NSCLC

August 28th 2018

D. Ross Camidge, MD, PhD, discusses the use of immunotherapy in patients with non–small cell lung cancer.

Expert Explains Successes, Challenges in Stage III Lung Cancer

August 28th 2018

Dustin M. Walters, MD, provides perspective on the treatment landscape of stage III non–small cell lung cancer.

Dr. Herbst Discusses Challenges With Immunotherapy in NSCLC

August 27th 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses challenges with immunotherapy in non–small cell lung cancer.

Dr. Feliciano on Nivolumab in Small Cell Lung Cancer

August 27th 2018

Josephine Louella Feliciano, MD, assistant professor of oncology, Johns Hopkins Medicine, discusses the use of nivolumab (Opdivo) in patients with small cell lung cancer (SCLC).

Dr. Naidoo on Managing Immune-Related Adverse Events in NSCLC

August 24th 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses managing immune-related adverse events (irAEs) in patients with non–small cell lung cancer (NSCLC).

Dr. Levy on Biomarkers of Response to Immunotherapy

August 24th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses biomarkers of response to immunotherapy.

Dr. Formenti on the Role of the Immune System in Cancer Treatment

August 24th 2018

Silvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the role of the immune system in cancer treatment.

Expert Highlights Promising Multiple Myeloma Data

August 24th 2018

Noopur Raje, MD, discusses the latest treatment advances in multiple myeloma.

Dr. Youngblood on the Process of T-Cell Differentiation in Pediatric Solid Tumors

August 23rd 2018

Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the process of T-cell differentiation in pediatric solid tumors.

Dr. Camidge on the KEYNOTE-024 Trial in NSCLC

August 23rd 2018

D. Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses implications of the KEYNOTE-024 trial in non–small cell lung cancer (NSCLC).

Dr. Galsky Discusses Neoadjuvant Immunotherapy in Bladder Cancer

August 22nd 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses neoadjuvant immunotherapy in bladder cancer.

Lead Investigator Discusses Pegilodecakin/PD-1 Inhibitor Combination in NSCLC

August 21st 2018

Edward B. Garon, MD, discusseds early findings with pegilodecakin in non–small cell lung cancer.

Dr. Tarhini on Recent Practice-Changing Clinical Trials in Melanoma

August 21st 2018

Ahmad Tarhini, MD, PhD, director, Melanoma and Skin Cancer Program, Center for Immuno-Oncology Research, Cleveland Clinic, discusses some recent practice-changing clinical trials in melanoma.